Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.39 |
| ▸ | DRD2 | P14416 | 7/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.35 |
| ▸ | HPGD | P15428 | 5/20 | 0.35 |
| ▸ | PKM | P14618 | 4/20 | 0.35 |
| ▸ | GLA | P06280 | 4/20 | 0.35 |
| ▸ | GAA | P10253 | 4/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | BCHE | P06276 | 1/20 | 0.33 |
| ▸ | NSD2 | O96028 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 3/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | CASP1 | P29466 | 1/20 | 0.32 |
| ▸ | CASP7 | P55210 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3946936 | 0.92 | ALDH1A1 (0.35) | ALDH1A1DRD2KDM4EHPGDPKM | |
| SCHEMBL3936552 | 0.86 | ALDH1A1 (0.45) | ALDH1A1DRD2KDM4EHPGDPKM | |
| SCHEMBL3936282 | 0.84 | ADORA2A (0.43) | ALDH1A1DRD2KDM4EHPGDGLA | |
| SCHEMBL3944905 | 0.80 | ALDH1A1 (0.38) | ALDH1A1DRD2KDM4EHPGDPKM | |
| SCHEMBL3936530 | 0.80 | ALDH1A1 (0.38) | ALDH1A1DRD2KDM4EHPGDPKM | |
| SCHEMBL3936237 | 0.80 | ALDH1A1 (0.35) | ALDH1A1DRD2KDM4EHPGDPKM | |
| SCHEMBL3943323 | 0.79 | ADORA2A (0.44) | ALDH1A1DRD2KDM4E | |
| SCHEMBL4332600 | 0.76 | ALDH1A1 (0.38) | ALDH1A1DRD2 | |
| SCHEMBL13843277 | 0.75 | JAK2 (0.36) | ALDH1A1DRD2KDM4EHPGDPKM | |
| SCHEMBL27676184 | 0.71 | DRD2 (0.35) | ALDH1A1DRD2KDM4EHPGDPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7528140-B2 | Substituted pyrrolo[3,2-d]pyrimidines as glycogen synthase kinase (GSK) inhibitors | TEIJIN LIMITED (JP) | 2009-05-05 | — | — | US | disclosed |
| US-20050277773-A1 | Pyrrolopyrimidine derivatives | TEIJIN LIMITED (JP) | 2005-12-15 | — | — | US | disclosed |
| CN-1633436-A | Pyrrolopyrimidine derivatives | TEIJIN LTD (JP) | 2005-06-29 | — | — | CN | disclosed |
| EP-1477489-A1 | PYRROLOPYRIMIDINE DERIVATIVES | TEIJIN LIMITED (JP) | 2004-11-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050277773-A1 | Pyrrolopyrimidine derivatives | GSK3B, GSK3A, GSKIP | ALDH1A1 2709/4885DRD2 2385/4885KDM4E 1378/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.